Findings support the HIV fusion peptide as a promising preventive vaccine target.

Thursday, January 18, 2024 NIH-Developed HIV Antibodies Protect Animals in Proof-of-Concept Study Transmission electron micrograph of HIV-1 virus particles (blue) from infected H9 cells, produced in cell culture. The particles exhibit two stages of replication: the two "arcs" are immature particles budding from the plasma membrane of the cell, and the center spherical particle is a mature form in extracellular space. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Three different HIV antibodies isolated by the NIAID Vaccine Research Center each independently protected monkeys from acquiring simian-HIV (SHIV) in a study intended to inform development of a preventive HIV vaccine for people. The antibodies target the fusion peptide, a site on an HIV surface protein that helps the virus fuse with and enter cells. According to the authors, these findings represent the proof-of-concept that fusion peptide-directed antibodies can provide protection against SHIV and help determine the concentration of antibodies a vaccine would need to generate to be protective. The findings are published in Science Translational Medicine. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107